BioSpace News Archive

Isofol Medical AB’s Board of Directors have, pursuant to the authorization granted by the extra general meeting on May 5, 2020, resolved on a fully guaranteed new share issue of a maximum of 42,739,736 shares with preferential rights for the Company’s existing shareholders.

Dr. Reddy’s Laboratories Ltd. will announce results for the fourth quarter and full year ended March 31, 2020 on Wednesday, May 20, 2020 after the Board Meeting.

Certara applying expertise in clinical pharmacology, innovation and collaboration to accelerate potential prophylaxis for COVID-19

Unprecedented program convenes manufacturers and pharmacies to help millions of Americans access prescription medications at affordable and predictable prices

Endo International plc reported financial results for the first quarter ended March 31, 2020 and provided an update relating to the impact of the COVID-19 pandemic.

BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced financial results for the first quarter ended March 31, 2020 and recent corporate updates.

Madrigal continued to make progress toward our clinical development and business objectives during the first quarter of 2020, despite challenges associated with the COVID-19 pandemic.

Cara Therapeutics, Inc. announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, and Joana Goncalves, M.D., Chief Medical Officer, will participate in a fireside chat at the virtual BofA Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 9:00 a.m. ET.

BioCryst Pharmaceuticals, Inc. announced that the company will present at the Bank of America 2020 Healthcare Conference on Thursday, May 14, 2020 at 9:00 a.m. ET and the 2020 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20, 2020 at 3:40 p.m. ET.

Evelo Biosciences, Inc., Rutgers University, and Robert Wood Johnson University Hospital announced the submission of an Investigational New Drug application for an Evelo-sponsored Phase 2 clinical study evaluating the safety and efficacy of EDP1815 for the treatment of hospitalized patients with newly diagnosed COVID-19.